Poxel
Business Services · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
259-261 Ave Jean Jaurès, Lyon, Auvergne-...Phone Number
+33 144719494Website
www.poxelpharma.comRevenue
$7.7 MillionStock Symbol
POXELIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
2
About Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases driven by metabolic dysfunction. Its pipeline focuses on liver and rare metabolic disorders, and it also receives royalty related revenue from a partnered diabetes therapy commercialized in Japan.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Poxel your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Poxel is spiking on competitors!
Click to see if Poxel had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Poxel has new funding data
Check if Poxel has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Poxel launches new products
Earning: See what the market has to say on Poxel recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Poxel, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Poxel
Recommended Actions
Find VP level buyers at Poxel
Find more new buyers
Company Profile Activity
Activity Insights
Poxel is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Poxel is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Poxel.
Poxel financials insights
Gather financial insights about Poxel, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$21M
2014
Series B
$13.5M
2020
Share Placement
$19.4M
Unspecified
$7M
2022
Debt
$6.1M
2026
Other Financing Round
$4.3M
Poxel Tech Stack
A closer look at the technologies used by Poxel
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Event
Events
Event
Events
Poxel News & Media
Metabolic Disease-Focused Poxel Teeters On The Edge - Citeline News & Insights
The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, today announces the postponement of its 2025 Annual General Meeting, which is intended to approve the financial statements for the year ended December 31, 2024, and providesPoxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the abstract featuring previously announced preclinical data demonstrating positive results for PXL065, the deuterium-stabilized R-enantiomer of pioglitPoxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2025 and provided corporate update. Thomas Kuhn, Chief Executive Officer of Poxel, stated: “TWYMEEG® has further dem
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Poxel
Sign Up For FreeTo access detailed company insights
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases driven by metabolic dysfunction. Its pipeline focuses on liver and rare metabolic disorders, and it also receives royalty related revenue from a partnered diabetes therapy commercialized in Japan.... Read More
